Cohance Lifesciences Ltd Q2 Revenue Rises, Profit Falls 96.5%

Cohance Lifesciences Ltd reported a 96.5% year-on-year fall in Q2 FY27 net profit to ₹2.27 crore, even as revenue rose 12.9% sequentially to ₹476.6 crore. The quarter showed a recovery from the preceding quarter, led by Pharma CDMO, but earnings remained materially below the year-ago level amid destocking, specialty chemicals weakness and regulatory constraints.

How did Cohance perform in Q2 FY27?

Cohance recorded revenue from operations of ₹476.6 crore in Q2 FY27, a 14.2% decline from the corresponding quarter a year earlier and a 12.9% increase from Q1 FY27. Sequential revenue improvement followed a weak first quarter, when revenue was about ₹420 crore.

Adjusted EBITDA rose to ₹45.9 crore from ₹9.2 crore in Q1 FY27. Consequently, adjusted EBITDA margin improved to 9.6% from 2.2% in the preceding quarter. However, the margin was well below 23.2% reported in Q2 FY26, when adjusted EBITDA stood at ₹128.8 crore.

Reported net profit was ₹2.27 crore, compared with ₹66.39 crore in Q2 FY26. Adjusted profit after tax turned positive at ₹7.4 crore, versus an adjusted loss position implied by the weak first-quarter operating performance, but it remained below the ₹70.9 crore adjusted PAT reported a year earlier.

What drove Cohance's sequential recovery?

Cohance said Pharma CDMO led the sequential improvement, with segment revenue increasing 34.5% quarter-on-quarter. Management attributed this increase primarily to a higher contribution from small molecules, indicating that activity in this business improved after the first quarter.

On the earnings call, management said Q2 performance was in line with its expected trajectory of sequential improvement followed by a return to year-on-year growth in the second half. It linked the anticipated H2 improvement to restocking of commercial molecules. No numerical revenue or margin guidance for H2 was provided in the material.

The company is pursuing a One Cohance integration strategy. Cohance is a single listed Indian entity controlled by Advent International and combines six formerly independent CDMO and API businesses along with two strategic US subsidiaries. The integration effort is intended to operate these businesses as one platform, although the quarter's reported figures remain the key measure for investors.

Why are year-on-year earnings still under pressure?

Cohance's year-on-year comparison remained weak because revenue was lower and adjusted EBITDA declined 64.4% from the year-ago quarter. The gap between the 9.6% Q2 FY27 EBITDA margin and the 23.2% margin a year earlier shows that the sequential recovery has not restored prior-period profitability.

Management identified destocking, weakness in specialty chemicals and regulatory uncertainty as continuing constraints. It also cut its FY27 specialty chemicals guidance to a decline, rather than maintaining an expectation of growth. The supplied material does not quantify the revised guidance or provide a segment-level revenue figure for specialty chemicals.

The company also disclosed that its Suryapet facility received a closure order following a fatal accident. Cohance said the operational and financial impact was under assessment. As a result, the available disclosures do not establish the likely duration of the disruption or its financial effect.

What does the quarter mean for Cohance investors and operations?

For investors, the quarter presents two different signals: revenue and adjusted EBITDA recovered meaningfully from Q1, while the year-on-year fall in profit remained severe. The reported profit of ₹2.27 crore and H1 FY27 net loss of ₹42.92 crore contrast with H1 FY26 profit of ₹112.79 crore, underlining the scale of the first-half earnings decline.

The improvement in EBITDA from ₹9.2 crore to ₹45.9 crore is relevant because it shows better operating leverage as revenue recovered sequentially. But the current margin remains less than half the prior-year level, leaving the pace of commercial-molecule restocking and the performance of specialty chemicals central to the financial trend.

For operations, the Suryapet closure order is an unresolved issue alongside the broader regulatory uncertainty referenced by management. Customers and business partners may monitor the company's assessment of any facility disruption, while shareholders will look for evidence that the expected H2 recovery can translate into year-on-year improvement.

What should investors monitor in the second half of FY27?

Investors should monitor whether Cohance delivers the year-on-year H2 growth indicated by management. The company has stated the direction of its expectation but has not provided revenue, EBITDA or margin targets for the second half.

The main operating indicators will be growth in Pharma CDMO, the contribution from small molecules, specialty chemicals performance and the status of the Suryapet facility. A sustained recovery would need to be visible in both revenue and margins, given that Q2 EBITDA margin was 9.6% against 23.2% a year earlier.

The company held its Q2 FY27 earnings call on 6 November 2026 after releasing unaudited Q2 and H1 FY27 results. The next quarterly disclosure will provide a clearer view of whether the sequential Q2 improvement has developed into the H2 year-on-year growth management expects.

Conclusion

Cohance Lifesciences Ltd delivered a sequential recovery in Q2 FY27, with revenue rising 12.9% quarter-on-quarter and adjusted EBITDA margin improving to 9.6%. Yet revenue remained 14.2% below the year-ago quarter, while reported net profit declined 96.5% to ₹2.27 crore, reflecting the continuing pressure on profitability.

The next results will be important for assessing management's H2 growth expectation. Investors should watch commercial-molecule restocking, the revised specialty chemicals outlook, the recovery in operating margin and the company's assessment of the Suryapet closure order.